Angeliki Vgenopoulou
Angeliki Vgenopoulou has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Martínez León
Saarland University
1 shared publication - Andreas Martin Kany
Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) Helmholtz Centre for Infection Research (HZI), Campus E8.1 Saarbrücken Germany
1 shared publication - Anna Katharina Herta Hirsch
Helmholtz Centre for Infection Research (HZI) − , Campus E8.1
1 shared publication - Gwenaëlle Jézéquel
Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) – Helmholtz Centre for Infection Research (HZI), Campus E 8.1, Saarbrücken, Germany, 66123
1 shared publication - Jochen S. Hub
Theoretical Physics and Center for Biophysics, Saarland University, 66123 Saarbrücken, Germany
1 shared publication
Latest Publications
- Open Access
Prospective discovery of LasB inhibitors by integrating generative design, free energy ranking, and experimental validation
Identifying synthetically accessible, potent ligands from vast chemical space remains a major challenge in drug discovery, particularly because experimental synthesis and testing are costly and low throughput. Here, we present a fully open-source computational–experimental workflow that integrates fragment-based de novo molecular design with rigorous alchemical absolute binding free-energy calculations to enable physics-based prioritization before chemical synthesis. We apply this strategy by targeting the virulence-associated zinc metalloprotease LasB from Pseudomonas aeruginosa. From ~40,000 diverse compounds generated through multi-objective optimization, a small subset was prioritized and experimentally evaluated, leading to the discovery of three previously unreported nanomolar inhibitors (IC 50 22–53 nM) with excellent metabolic and plasma stability. This work demonstrates a general and scalable framework for coupling generative molecular design with quantitative binding affinity prediction, improving decision-making and reducing the cost, time, and risk associated with early-stage drug discovery.
Open AccessProspective discovery of LasB inhibitors by integrating generative design, free energy ranking, and experimental validation
Identifying synthetically accessible, potent ligands from vast chemical space remains a major challenge in drug discovery, particularly because experimental synthesis and testing are costly and low throughput. Here, we present a fully open-source computational–experimental workflow that integrates fragment-based de novo molecular design with rigorous alchemical absolute binding free-energy calculations to enable physics-based prioritization before chemical synthesis. We apply this strategy by targeting the virulence-associated zinc metalloprotease LasB from Pseudomonas aeruginosa. From ~40,000 diverse compounds generated through multi-objective optimization, a small subset was prioritized and experimentally evaluated, leading to the discovery of three previously unreported nanomolar inhibitors (IC 50 22–53 nM) with excellent metabolic and plasma stability. This work demonstrates a general and scalable framework for coupling generative molecular design with quantitative binding affinity prediction, improving decision-making and reducing the cost, time, and risk associated with early-stage drug discovery.